Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
2mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Targets |
Bradykinin B2 Receptor (B2R)
|
---|---|
ln Vitro |
Icatibant (10–30 μM) increases the effects of angiotensin III, but not II (contraction mediated by angiotensin AT1 receptors), and Lys-des-Arg9-bradykinin, but not des-Arg9-bradykinin (effects mediated by the bradykinin B1 receptors) (see reference 3).
|
ln Vivo |
Icatibant (0.3, or 1.5 mg/kg, subcutaneous administration twice daily in mice) significantly reduces the risk of ulcerative colitis[2].
|
Animal Protocol |
Female mice of the CBA/J (H-2k) strain
0.06, 0.3, or 1.5 mg/kg. Subcutaneous administration twice daily |
References |
|
Molecular Formula |
C59H89N19O13S
|
---|---|
Molecular Weight |
1304.5225
|
Exact Mass |
1303.66
|
Elemental Analysis |
C, 54.32; H, 6.88; N, 20.40; O, 15.94; S, 2.46
|
CAS # |
130308-48-4
|
Related CAS # |
Icatibant acetate; 138614-30-9
|
Appearance |
Solid powder
|
SMILES |
C1CC[C@H]2[C@@H](C1)C[C@H](N2C(=O)[C@H]3CC4=CC=CC=C4CN3C(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=CS5)NC(=O)CNC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H]7CCCN7C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O
|
InChi Key |
QURWXBZNHXJZBE-SKXRKSCCSA-N
|
InChi Code |
InChI=1S/C59H89N19O13S/c60-37(14-5-19-67-57(61)62)48(82)72-38(15-6-20-68-58(63)64)52(86)75-22-8-18-43(75)54(88)77-30-35(80)26-44(77)50(84)70-28-47(81)71-40(27-36-13-9-23-92-36)49(83)74-41(31-79)53(87)76-29-34-12-2-1-10-32(34)24-46(76)55(89)78-42-17-4-3-11-33(42)25-45(78)51(85)73-39(56(90)91)16-7-21-69-59(65)66/h1-2,9-10,12-13,23,33,35,37-46,79-80H,3-8,11,14-22,24-31,60H2,(H,70,84)(H,71,81)(H,72,82)(H,73,85)(H,74,83)(H,90,91)(H4,61,62,67)(H4,63,64,68)(H4,65,66,69)/t33-,35+,37+,38-,39-,40-,41-,42-,43-,44-,45-,46+/m0/s1
|
Chemical Name |
(2S)-2-[[(2S,3aS,7aS)-1-[(3R)-2-[(2S)-2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-[(2S)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid
|
Synonyms |
Firazyr; Icatibant
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O: ~100 mg/mL (~76.7 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (38.33 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 0.7666 mL | 3.8328 mL | 7.6657 mL | |
5 mM | 0.1533 mL | 0.7666 mL | 1.5331 mL | |
10 mM | 0.0767 mL | 0.3833 mL | 0.7666 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05509569 | Recruiting | Drug: Icatibant | Hereditary Angioedema (HAE) |
Takeda | August 24, 2022 | N/A |
NCT01034969 | Recruiting | N/A | Hereditary Angioedema (HAE) |
Shire | July 10, 2009 | N/A |
NCT05834777 | Recruiting | Drug: Icatibant Drug: Placebo |
Intradialytic Hypotension | Vanderbilt University Medical Center |
December 11, 2023 | Phase 3 |
NCT04113109 | Recruiting | Drug: Icatibant Drug: placebo |
Heart Failure | Vanderbilt University Medical Center |
November 1, 2019 | Phase 4 |
NCT03888755 | Completed | Drug: Icatibant | Hereditary Angioedema (HAE) |
Shire | March 18, 2015 | Phase 3 |